Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2009

01-12-2009 | Original Article

Differential expression of tenascin-C in the developing human lung: an immunohistochemical study

Authors: M. Lambropoulou, V. Limberis, N. Koutlaki, M. Simopoulou, D. Ntanovasilis, G. P. Vandoros, P. Tatsidou, I. Kekou, I. Koutsikogianni, N. Papadopoulos

Published in: Clinical and Experimental Medicine | Issue 4/2009

Login to get access

Abstract

Much of the specification for the basic embryonic body plan is the result of a hierarchy of developmental decisions at different developmental times. The extracellular matrix (ECM) appears to be a very dynamic structure during embryogenesis. One of the mesenchymal ECM proteins, tenascin, is reported to be transiently expressed during embryonic tissue development, and is absent or much reduced in most fully developed organs. The respiratory system is an outgrowth of the ventral wall of the foregut, and the epithelium of the larynx, trachea, bronchi and alveoli is of endodermal origin. The cartilaginous and muscular components are of mesodermal origin. The aim of this study was to investigate the role of tenascin-C (TNC) in the developing human lung, during the pseudoglandular, canalicular and saccular stage of lung maturation. Formalin-fixed, paraffin-embedded tissue from the lungs of 30 embryos (10 corresponding to the 10th to the 16th gestational week (pseudoglandular stage), 10 to the 17th to the 23rd gestational week (canalicular stage), and 10 to the 24th to the 27th gestational week (saccular stage), were investigated by conventional histology and immunohistology for the expression levels of TNC. The changes observed in the distribution patterns suggest that during embryogenesis, the rate of tenascin synthesis changes significantly. During the pseudoglandular stage, the density of cells expressing TNC was higher in the condensing mesenchyme surrounding the epithelial glands than in the epithelial cells, whereas the inverse result was observed during the canalicular stage. During the saccular stage the pattern of immunoreactivity with TNC was lower than those of the pseudoglandular and canalicular stage, either in epithelial or mesenchymal cells, but it was highly expressed in the basement membranes. This restricted spatiotemporal distribution suggests that tenascin has a key role (1) in mesenchymal tissue remodeling during the pseudoglandular stage, a period that describes the development of the complete bronchial tree and (2) on the epithelial cell shape and function during the canalicular stage, a period that describes the formation of pneumocytes type I and pneumocytes type II. The later, will produce the surfactant, a phospholipid-rich fluid capable of lowering surface tension at the air–alveolar interface. During the saccular stage, tenascin was present mainly in the basement membranes surrounding the acinar and vascular structures, indicating a supporting and mechanical role.
Literature
1.
go back to reference (1995) Gray’s anatomy, 38th edn. Churchill Livingstone, New York, p 179 (1995) Gray’s anatomy, 38th edn. Churchill Livingstone, New York, p 179
2.
go back to reference Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T (1986) Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47(1):131–139PubMedCrossRef Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T (1986) Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47(1):131–139PubMedCrossRef
3.
go back to reference Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244(2):143–163PubMedCrossRef Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244(2):143–163PubMedCrossRef
4.
go back to reference Ishii K, Imanaka-Yoshida K, Yoshida T, Sugimura Y (2008) Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Dev Biol 324(2):310–319PubMedCrossRef Ishii K, Imanaka-Yoshida K, Yoshida T, Sugimura Y (2008) Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Dev Biol 324(2):310–319PubMedCrossRef
5.
go back to reference Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200(4):488–499PubMedCrossRef Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200(4):488–499PubMedCrossRef
6.
go back to reference Chiquet-Ehrismann R (1995) Tenascins, a growing family of extracellular matrix proteins. Experientia 51(9–10):853–862PubMedCrossRef Chiquet-Ehrismann R (1995) Tenascins, a growing family of extracellular matrix proteins. Experientia 51(9–10):853–862PubMedCrossRef
7.
go back to reference Jones PL, Jones FS (2000) Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19(7):581–596PubMedCrossRef Jones PL, Jones FS (2000) Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19(7):581–596PubMedCrossRef
8.
go back to reference Sternberger LA (1974) Immunocytochemistry. Prentice-Hall, Englewood Cliffs, pp 129–171 Sternberger LA (1974) Immunocytochemistry. Prentice-Hall, Englewood Cliffs, pp 129–171
9.
go back to reference Mackie EJ, Thesleff I, Chiquet-Ehrismann R (1987) Tenascin is associated with chondrogenic and osteogenic differentiation in vivo and promotes chondrogenesis in vitro. J Cell Biol 105:2569–2579PubMedCrossRef Mackie EJ, Thesleff I, Chiquet-Ehrismann R (1987) Tenascin is associated with chondrogenic and osteogenic differentiation in vivo and promotes chondrogenesis in vitro. J Cell Biol 105:2569–2579PubMedCrossRef
10.
go back to reference Mackie EJ, Chiquet-Ehrismann R, Pearson CA et al (1981) Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84:4621–4625CrossRef Mackie EJ, Chiquet-Ehrismann R, Pearson CA et al (1981) Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84:4621–4625CrossRef
11.
go back to reference Thesleff I, Kantomaa T, Mackie EJ et al (1988) Immunohistochemical localization of the matrix glycoprotein tenascin in the skull of the growing rat. Arch Oral Biol 33:383–390PubMedCrossRef Thesleff I, Kantomaa T, Mackie EJ et al (1988) Immunohistochemical localization of the matrix glycoprotein tenascin in the skull of the growing rat. Arch Oral Biol 33:383–390PubMedCrossRef
12.
go back to reference Ekblom P, Aufderheide E (1989) Stimulation of tenascin expression in mesenchyme by epithelial–mesenchymal interactions. Int J Dev Biol 33:71–79PubMed Ekblom P, Aufderheide E (1989) Stimulation of tenascin expression in mesenchyme by epithelial–mesenchymal interactions. Int J Dev Biol 33:71–79PubMed
13.
go back to reference Engel J (1989) EGF-like domains in extracellular matrix proteins: localized signals for growth and differentiation? FEBS Lett 251:1–7PubMedCrossRef Engel J (1989) EGF-like domains in extracellular matrix proteins: localized signals for growth and differentiation? FEBS Lett 251:1–7PubMedCrossRef
14.
go back to reference Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I (1991) Tenascin in normal, reactive, hyperplastic, and neoplastic tissues; biologic and pathologic implications. Hum Pathol 22(7):636–643PubMedCrossRef Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I (1991) Tenascin in normal, reactive, hyperplastic, and neoplastic tissues; biologic and pathologic implications. Hum Pathol 22(7):636–643PubMedCrossRef
Metadata
Title
Differential expression of tenascin-C in the developing human lung: an immunohistochemical study
Authors
M. Lambropoulou
V. Limberis
N. Koutlaki
M. Simopoulou
D. Ntanovasilis
G. P. Vandoros
P. Tatsidou
I. Kekou
I. Koutsikogianni
N. Papadopoulos
Publication date
01-12-2009
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 4/2009
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-009-0057-x

Other articles of this Issue 4/2009

Clinical and Experimental Medicine 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.